carcinoGENOMICS.eu: Home
http://www.carcinogenomics.eu/index.php?id=100

carcinoGENOMICS - a project of the European Union

Welcome to carcinoGENOMICS

The aim of the FP6 project carcinoGENOMICS is to develop in vitro methods for assessing the carcinogenic potential of compounds, as an alternative to current rodent bioassays for genotoxicity and carcinogenicity. The major goal is to develop a battery of mechanism-based in vitro tests accounting for various modes of carcinogenic action. These tests will be designed to cover major target organs for carcinogenic action e.g. the liver, the lung and the kidney. The novel assays will be based on the application of "omics" technologies (i.e. genome-wide transcriptomics as well as metabonomics) to robust in vitro systems (rat/human), thereby also exploring stem cell technology, to generate "omic" responses from a well-defined set of model compounds causing genotoxicity and carcinogenicity. Phenotypic markers for genotoxic and carcinogenic events will be assessed for the purpose of anchoring gene expression modulations, metabolic profiles and mechanistic pathways. Through extensive biostatistics, literature mining, and analysis of molecular-expression datasets, differential genetic pathways will be identified capable of predicting mechanisms of chemical carcinogenesis in vivo.

Furthermore, generated transcriptomic and metabonomic data will be integrated into a holistic understanding of systems biology, and applied to build an iterative in silico model of chemical carcinogenesis. Subsequently, predictive genetic pathways will be used as the scientific basis to develop high throughput technology for accelerating analysis of genomics responses in vitro, indicative for human carcinogenic risk, by a factor of 100.

It is expected that the outcome of this project will generate a platform enabling the investigation of large numbers of compounds for their genotoxic and carcinogenic potential. This will contribute to speeding the identification of potential harmful substances to man, while lowering costs and reducing animal tests.

Adobe PDFDownload the flyer of the carcinoGENOMICS project (616 kb)

Booklet on alternative testing strategies

This booklet has been published by DG Research. It gives a good overview of FP6 and FP7 projects.

Adobe PDFAlternative Testing Strategies - Progress Report 2009 (5.3 MB)

Upcoming Event

Workshop: Genomics in Cancer Risk Assessment
27-28 August 2009, in Venice, Italy

You may now register for the Workshop: Genomics in Cancer Risk Assessment that will be held on 27-28 August 2009, in Venice, Italy.

Please register through: http://www.hesiglobal.org/Committees/TechnicalCommittees/Genomics/Genomics_CRA_Venice.htm

This Workshop entitled "Implementation of Genomic Approaches with both In Vitro and In Vivo Models for Use in Cancer Risk Assessment" with the purpose to engage leading US and EU scientists and health policy decision makers in the potentials and challenges that the "omics" technologies bring to cancer risk assessment is organized by the EU carcinoGENOMICS project, the Netherlands Toxicogenomics Centre (NTC), ecopa, ECVAM, NIEHS US, HESI/ILSI US and Pfizer US.

This workshop is accepted as a parallel meeting of the "10th International Conference on Environmental Mutagens" in Florence (Aug. 20-25 http://www.icem2009.org/eems/conference09/default.csp) and the "7th World Congress on alternatives and animal use in the life sciences" in Rome (Aug. 30-Sept 3, 2009 http://www.aimgroup.eu/2009/WC7/geninfo.html).

On behalf of the Organizing Committee: Jos Kleinjans (Maastricht University), Richard Paules (NIEHS), Jiri Aubrecht (Pfizer), Bernward Garthoff (Bayer CropScience), Raffaella Corvi (EC ECVAM), Raegan O'Lone (HESI/ILSI), Anneloes Melman (Maastricht University) and René Reijnders (Maastricht University).

Booklet on alternative testing strategies

This booklet has been published by DG Research. It gives a good overview of FP6 and FP7 projects.

Adobe PDFDownload the booklet (1.7 MB)

Questionnaire

One of the project goals is to identify the best way forward towards identification of crucial criteria for the development and validation of in vitro models in the carcinoGENOMICS project, in order to obtain regulatory acceptance of these models Specifically, the following questions will be addressed:

We would appreciate to have your input concerning the above mentioned questions.

Latest additions
Most popular